Cours Coeptis Therapeutics, Inc. OTC Markets
Actions
COEP
US19207C1045
Produits pharmaceutiques
CA 2024 * | - | CA 2025 * | - | Capitalisation | 12,08 M 11,04 M |
---|---|---|---|---|---|
Résultat net 2024 * | -26 M -23,75 M | Résultat net 2025 * | -35 M -31,97 M | VE / CA 2024 * | - |
Trésorerie nette 2024 * | - 0 | Trésorerie nette 2025 * | - 0 | VE / CA 2025 * | - |
PER 2024 * |
-0,43
x | PER 2025 * |
-0,38
x | Employés | 6 |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 67,46% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 28/10/22 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 17/05/23 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28/10/22 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Director/Board Member | 62 | 28/10/22 | |
Director/Board Member | 55 | 28/10/22 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 28/10/22 |
Varia. 1 janv. | Capi. | |
---|---|---|
+25,83% | 661 Md | |
+27,00% | 566 Md | |
-6,76% | 352 Md | |
+20,34% | 332 Md | |
+3,00% | 283 Md | |
+13,09% | 231 Md | |
+5,46% | 200 Md | |
-9,61% | 195 Md | |
-6,26% | 145 Md |